

ISSN 0120-4157

# Biomédica

Revista del Instituto Nacional de Salud

## PUBLICACIÓN ANTICIPADA EN LINEA

El Comité Editorial de *Biomédica* ya aprobó para publicación este manuscrito, teniendo en cuenta los conceptos de los pares académicos que lo evaluaron. Se publica anticipadamente en versión pdf en forma provisional con base en la última versión electrónica del manuscrito pero sin que aún haya sido diagramado ni se le haya hecho la corrección de estilo.

Siéntase libre de descargar, usar, distribuir y citar esta versión preliminar tal y como lo indicamos pero, por favor, recuerde que la versión impresa final y en formato pdf pueden ser diferentes.

### Citación provisional:

**García-Salazar E, Benavidez-López S, Bonifaz A, Hernández-Mendoza EA, Ramírez-Magaña X, Reyes-Montes MR, et al.** Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in México. *Biomédica*. 2024;44 (3).

Recibido: 22-10-23

Aceptado: 02-04-24

Publicación en línea: 03-04-24

**Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital  
in Mexico**

**Coinfección/sobreinfección fúngica en pacientes con COVID-19 en un  
hospital de tercer nivel en México**

**Fungal coinfection/superinfection in COVID-19 patients**

Eduardo García-Salazar <sup>1</sup>, Sandra Benavidez-López <sup>1</sup>, Alexandro Bonifaz <sup>2</sup>, Emma Alejandra Hernández-Mendoza <sup>1</sup>, Xóchitl Ramírez-Magaña <sup>1</sup>, María del Rocío Reyes-Montes <sup>2</sup>, Esperanza Duarte-Escalante <sup>2</sup>, Gustavo Acosta-Altamirano <sup>1</sup>, María Guadalupe Frías-De-León <sup>1</sup>

<sup>1</sup> Hospital Regional de Alta Especialidad de Ixtapaluca, Pueblo de Zoquiapan, Ixtapaluca, México

<sup>2</sup> Laboratorio de Micología, Servicio de Dermatología, Hospital General de México "Dr. Eduardo Liceaga", Ciudad de México, México

<sup>3</sup> Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.

**Correspondence:**

María Guadalupe Frías-De-León, Carretera Federal México-Puebla Km. 34.5, Pueblo de Zoquiapan, Ixtapaluca 56530, México.

Tel.: 55 5972 9800 ext. 1256

[magpefrias@gmail.com](mailto:magpefrias@gmail.com)

**Author contributions:**

María Guadalupe Frías-De-León and Eduardo García-Salazar: study conception and design.

Sandra Benavidez-López, Emma Alejandra Hernández-Mendoza, Xóchitl Ramírez-Magaña, María del Rocío Reyes-Montes, Esperanza Duarte-Escalante and Gustavo Acosta-Altamirano: data collection.

Alexandro Bonifaz: critical review of important intellectual content.

All authors reviewed and analysis of results, participated in writing the manuscript, and approved the final version of the manuscript.

**Introduction.** Data on the prevalence of fungal coinfections/superinfections in patients with COVID-19 are limited.

**Objective.** To describe the prevalence of fungal coinfections/superinfections in patients with COVID-19, as well as risk factors and demographic, clinical, and microbiological characteristics in a tertiary hospital in Mexico.

**Material and methods.** Patients with a confirmed COVID-19 diagnosis and a confirmed fungal infection hospitalized in the ICU from March 2020–December 2021 were included. Data on age, sex, comorbidities, hospital length of stay (days), laboratory (ferritin) and microbiological results, treatment for COVID-19, antifungal therapy, and outcome were obtained from the clinical record.

**Results.** 11/740 patients met the inclusion criteria. The coinfection and superinfection rates were 0.3% and 1.2%, respectively. The most affected population was male adults. The coinfections/superinfections diagnosed were candiduria and candidemia, caused by *Candida albicans*, *C. tropicalis*, *C. glabrata*, *C. lusitanae*, and *Kluyveromyces marxianus* (*C. kefyr*). In addition, tracheobronchitis due to *Aspergillus fumigatus* was found. The most used antifungals were fluconazole and caspofungin. The lethality in patients with fungal coinfections and superinfections was 50% and 22%, respectively. The length of hospital stay was 11-65 days. Eight patients required mechanical ventilation and six received corticosteroids. The main comorbidity was diabetes mellitus (81.8%).

**Conclusions.** The rate of fungal coinfections/superinfections in COVID-19 patients was low, but the lethality found urges for routine fungal screening in patients with

severe COVID-19 to timely detect fungal infections that may further compromise the patient's life.

**Keywords:** Mycoses; COVID-19; candidemia; aspergillosis; México.

**Introducción.** Los datos sobre la prevalencia de coinfecciones/sobreinfecciones fúngicas en pacientes con COVID-19 son limitados.

**Objetivo.** Describir la prevalencia de coinfecciones/sobreinfecciones fúngicas en pacientes con COVID-19, así como los factores de riesgo y las características demográficas, clínicas y microbiológicas en un hospital de tercer nivel en México.

**Material y métodos.** Se incluyeron pacientes con diagnóstico confirmado de COVID-19, hospitalizados en la UCI y con infección fúngica confirmada, durante marzo 2020–diciembre 2021. Del expediente clínico se obtuvieron datos sobre edad, sexo, comorbilidades, días de estancia hospitalaria, resultados de laboratorio (ferritina) y microbiológicos, tratamiento contra COVID-19, terapia antifúngica y desenlace.

**Resultados.** 11/740 pacientes cumplieron con los criterios de inclusión, las tasas de coinfección y sobreinfección fueron de 0.3 y 1.2%, respectivamente. La población más afectada fue la de varones adultos. Las coinfecciones/sobreinfecciones diagnosticadas fueron candiduria y candidemia, causadas por *Candida albicans*, *C. tropicalis*, *C. glabrata*, *C. lusitaniae* y *Kluyveromyces marxianus* (*C. kefyr*). Además, se encontró una traqueobronquitis por *Aspergillus fumigatus*. Los antifúngicos más empleados fueron fluconazol y caspofungina. La letalidad en pacientes con coinfecciones y sobreinfecciones fúngicas fue del 50% y 22%, respectivamente. El tiempo de estancia intrahospitalaria fue de 11-65 días. Ocho de los pacientes requirieron ventilación mecánica, y seis recibieron corticoides. La principal comorbilidad fue diabetes mellitus (81.8%).

**Conclusiones.** La tasa de coinfecciones/sobreinfecciones por hongos en pacientes con COVID-19 fue baja, pero la letalidad encontró la necesidad de realizar pruebas de detección de hongos de rutina en pacientes con COVID-19 grave para detectar oportunamente infecciones por hongos que puedan comprometer aún más la vida del paciente.

**Palabras clave:** micosis; COVID-19; candidemia; aspergilosis; México.

Similarly, to what has occurred in other respiratory virus epidemics, during the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), various events arose that not only further complicated the therapeutic management of patients but also increased considerably the mortality rate, mainly in those who had a dysregulated immune system as they developed severe forms of the disease (1-5). The presence of coinfections caused by viruses, bacteria, or fungi at the time of the diagnosis of SARS-CoV-2 infection or the subsequent development of superinfections were among these events (4-8). Among fungal coinfections, the genus *Aspergillus* has stood out as the most frequently associated pathogen, while species of the genus *Candida* have been the most identified in superinfections, including the multiresistant species *C. auris* (9-11). Other less frequently reported fungi among the population with COVID-19 are *Histoplasma capsulatum*, *Coccidioides* spp., *Cryptococcus* spp., *Pneumocystis jirovecii*, *Fusarium* spp., *Scedosporium* spp., *Trichosporon asahii*, *Mucor* spp., and *Rhizopus* spp.; the latter emerged causing a severe additional health problem, mainly in India (12-15). According to reports in different parts of the world, data on the prevalence of fungal coinfection/superinfection among COVID-19 patients are variable (2,8,14,16). Overall, the prevalence of coinfections was reported in the range of 4-12.6%, and superinfections between 6 and 8% (2,8,17-19). However, it is essential to consider that this wide range of prevalence may be due partly to the difficulty in differentiating COVID-19 from fungal infection based on clinical or radiological data



alone. Therefore, it is likely that many fungal coinfections or superinfections have gone unnoticed because of these diagnosis limitations (20).

Unfortunately, data on the prevalence, etiology, and outcomes of fungal coinfection and superinfection cases in patients with COVID-19 are limited compared to data on bacterial or viral coinfections/superinfections (8). This situation prompts the need for continuously sharing information regarding the prevalence of coinfections and superinfections in hospitalized COVID-19 patients (21). Even though on May 5, 2023, the World Health Organization announced the end of the health emergency worldwide, after more than three years of announcing the pandemic, it does not mean that COVID-19 has stopped being a threat to global health. Thus, it is crucial to have a broad overview of coinfections and superinfections, especially the fungal ones, to prevent, detect and treat them promptly, thus improving the prognosis of affected people.

The objective of this study was to describe the prevalence of fungal coinfections/superinfections in patients hospitalized due to COVID-19, as well as risk factors, demographic, clinical, and microbiological characteristics in a "COVID hospital" in Mexico, during the period March 2020 – December 2021.

## **Materials and methods**

### ***Study design***

An observational, retrospective, and cross-sectional study in patients hospitalized in the Intensive Care Unit (ICU) due to COVID-19, who presented associated fungal coinfections/superinfections. The study covered the period from March 17, 2020, when the first COVID-19 patient was received, until December 31, 2021. The

study was approved by the hospital's Research and Research Ethics committees (NR-15-2020). Due to the type of study, no informed consent was received from the patients. Patient-identifiable information was treated as confidential.

#### *Inclusion criteria*

Patients diagnosed with COVID-19 confirmed by molecular detection of the SARS-CoV-2 virus, hospitalized from March 17, 2020 – December 31, 2021, and diagnosed with fungal infection (fungemia, urinary tract infection, among others).

#### *Exclusion criteria*

Patients with fungal isolation without clinical relevance (*Candida* spp. in bronchoalveolar lavage (BAL), sputum, and bronchial aspirates).

#### ***Elimination criteria***

Patients with incomplete clinical records.

#### ***Definitions***

Coinfection was defined as a community-acquired infection diagnosed in the first 48 hours of hospital admission due to COVID-19. Superinfections were considered infections acquired 48 hours after hospital admission.

#### ***Data collection***

The hospital's clinical laboratory information system records were reviewed to identify ICU patients with positive mycological results reported during the study period. *Candida* species were identified using the automated VITEK® 2 (BioMérieux, Marcy l'Etoile, France) (22). For this purpose, a suspension was prepared with pure subcultures of the yeast isolates in NaCl (0.45%), and the turbidity was adjusted to a 2.0 McFarland Standard. With this suspension, the

VITEK® 2 system automatically filled, sealed, and incubated the individual test cards. The cards were incubated at 35.5 °C for 18 hours, and optical density readings were taken automatically every 15 minutes. From these readings, an identification profile was established and compared with the database, generating the final yeast identification. Final identifications listed as "excellent," "very good," "good," "acceptable," or "low discrimination" were considered correct. The *Aspergillus* isolate was identified based on its macro- and micro-morphological characteristics (23). After patients were selected, their electronic medical record was reviewed through the Saludness system (24) to obtain the following information: demographic data (sex, age), comorbidities, hospital length of stay, treatment for COVID-19, risk factors for fungal infection, laboratory (ferritin) and microbiological results (blood and urine cultures, respiratory samples), antifungal therapy and outcome (mortality).

### ***Data analysis***

Continuous data were presented as mean  $\pm$  standard deviation (SD), while categorical data were given as absolute numbers and percentage.

### **Results**

During the study period, 880 COVID-19 patients were admitted to the hospital's ICU, of which 740 had a positive SARS-CoV-2 PCR test. Isolation of fungal agents of the genus *Candida* or *Aspergillus* was reported in 26 patients. However, only 11 patients met the study inclusion criteria. Overall, the rate of fungal infection in COVID-19 patients was 1.5% (11/740). Analyzing the data by infection subtype, we found that 9/740 (1.2%) of the patients included in the study were diagnosed with

fungal superinfections. Fungal coinfections were recorded in 2/740 (0.3%) patients only. The time between the COVID-19 diagnosis and the detection of fungal infections was 2-60 days. 72.7% (8/11) of the population with fungal infection were males, and 27.3% (3/11) were females. The patients' age range was 22 to 72 years ( $50.4 \pm 15.4$ ).

The superinfections diagnosed were six cases of urinary tract infections, two cases of candidemia, and one tracheobronchitis due to *Aspergillus fumigatus*. The coinfections were two cases of urinary tract infections. The causative agents of urinary tract infections were *Candida albicans* (5), *C. tropicalis* (1), and *C. glabrata* (1), and one case had simultaneous isolation of *C. tropicalis* and *Kluyveromyces marxianus* (*C. kefyr*). Candidemias were caused by *C. tropicalis* (1) and *C. lusitaniae* (1). Fungal superinfections were treated with fluconazole (4), caspofungin (4), and voriconazole (1), while two patients did not receive antifungal treatment. One of these patients did not receive treatment because he died on the same day the mycosis was diagnosed, and the other patient requested to be transferred to another hospital to continue treatment. The overall case fatality rate among the study population was 27.3% (3/11). Looking at the infection subtype, we observed that the lethality in patients with fungal coinfections was 50% (1/2), while in patients who presented fungal superinfections was 22% (2/9).

The length of hospital stay was 11 to 65 days ( $29.3 \pm 17.5$ ). Eight patients received mechanical ventilation for 21-34 days. It is worth mentioning that one patient required mechanical ventilation on two occasions (table 1).

Of the 11 patients included in this study, 81.8% (9/11) presented comorbidities, the most frequent being type 2 diabetes mellitus (6), followed by systemic arterial hypertension (SAH) (3), chronic kidney disease (3), obesity (2), dyslipidemia (1), acute myeloid leukemia (1), acute lymphoblastic leukemia (1) and alcoholism (1). Regarding the treatment for COVID-19, six patients (54.5%) received corticosteroids (dexamethasone and methylprednisolone), and five of these patients received combined treatment with broad-spectrum antibiotics. Four patients (36.4%) received antibiotic therapy, with azithromycin being the most used, followed by ceftriaxone (3), vancomycin (3), cefepime (2), amikacin (2), levofloxacin (1), meropenem (1), and piperacillin/tazobactam (1). One patient (9.1%) was treated only with paracetamol.

## **Discussion**

In Mexico, the COVID-19 pandemic affected more than 7,614,771 people, killing 334,107 (25). This high lethality was mainly associated with diseases such as type 2 diabetes mellitus, SAH, and cardiovascular diseases. However, it is essential to mention that fungal/bacterial/viral coinfections/superinfections probably contributed to this lethality also, as documented in other epidemics/pandemics caused by respiratory viruses, such as the ones causing SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), influenza A(H1N1), parainfluenza, as well as rhinovirus, adenovirus, respiratory syncytial virus, and cytomegalovirus (26-30).

Also, the prevalence of secondary infections in each epidemic/pandemic has varied. For example, 25 to 30% of the SARS survivor population was estimated

to develop a coinfection/superinfection by another microorganism (31).

Unfortunately, the issue of COVID-19-associated infections has not been sufficiently explored, let alone secondary fungal infections (32). Therefore, in this work, we report the prevalence of fungal coinfections/superinfections in patients hospitalized due to COVID-19 in a hospital center dedicated to providing exclusive care for this condition during the pandemic. Our results yielded a rate of fungal coinfections/superinfections of 1.5%, showing that superinfections (1.2%) were more frequent than coinfections (0.3%). The previous coincides with that reported by Musuuza et al. (8), who determined a frequency of 8% for superinfections and 4% for coinfections.

However, the rate of fungal coinfections/superinfections (1.5%) we reported was lower than those observed in other studies, which ranged from 4-12% (2,8,17-19). This discrepancy can be attributed to the fact that those rates were calculated in systematic review studies and meta-analyses which compiled all data reported on this topic from the end of 2019 to mid-2021, which was the most complicated period of the COVID-19 pandemic and, therefore, includes a large number of patients from different parts of the world (1,2,8,17-19). However, despite the small number of patients included in our study, the data is consistent with that obtained by García-Vidal et al. (33), who reported a low fungal infection rate (0.7%) in a Spanish population of 989 patients hospitalized for COVID-19.

In this way, some of the factors that may be involved in the low rate of fungal infection found are 1) underdiagnosis, since fungal screening was not routinely performed in patients; 2) limited diagnostic methods for mycoses, as only cultures

were used for isolating the pathogen; however, even though this is not the most sensitive diagnostic method (34). Unfortunately, some mycoses might have gone unnoticed as no molecular methods were utilized.

Data in this work also showed that the most affected population with fungal coinfections/superinfections associated with COVID-19 were male adults in the ICU with a median age of 58.5 years, which coincided with reports in other countries (14,35-37).

In addition, following other reports, urinary tract and bloodstream infections caused by the genus *Candida* were the predominant infections in the studied population, which were related to the use of urinary catheters, prolonged hospitalization time, and use of broad-spectrum antibiotics (33). On the other hand, tracheobronchitis, characterized by plaques in the large airways (trachea and bronchi), was the only manifestation of invasive aspergillosis that we found in a patient who required mechanical ventilation for a prolonged period, which possibly predisposed to mycosis (33). Tracheobronchitis has been reported in 10-20% of critically ill COVID-19 patients with a low frequency (38,39). In addition, it has been speculated that the development of tracheobronchitis is most likely due to epithelial erosion caused by viral replication. This condition is a predisposing factor since the damaged epithelium may be a pathway that facilitates the entry, colonization, and proliferation of *Aspergillus* in the respiratory tract (40).

Likewise, the primary etiological agent identified in candidiasis was *C. albicans*, while *A. fumigatus* was in aspergillosis. Both pathogens have been the most reported in COVID-19-associated mycoses (14,17,19), although *Mucor* spp. and

*Rhizopus* spp. are also frequently associated pathogens (14). In addition, the most used antifungal treatment for candidiasis cases was fluconazole and caspofungin for aspergillosis, contrary to the management with voriconazole that Sayedjavadi et al. (14) reported while treating 181 COVID-19 patients coinfecting mainly with *Aspergillus* spp., *Candida* spp., *Mucor* spp., and *Rhizopus* spp.

On the other hand, the 11 patients included in this study presented several conditions that were not mutually exclusive that acted as predisposing factors to fungal infection or any other type of infection. Among these factors, we found in seven patients the inhibition of the immune system associated with corticosteroids treatment (methylprednisolone, dexamethasone) for COVID-19 and broad-spectrum antibiotics (azithromycin, ceftriaxone, vancomycin, cefepime, amikacin, levofloxacin, meropenem, and piperacillin-tazobactam), mechanical ventilation indicated for an extended period (21-34 days), prolonged hospital stay in the ICU (mean 26 days), and elevated ferritin levels (456.4-1622 ng/mL) (36,41,42). In addition to these factors, comorbidities, particularly type 2 diabetes mellitus, SAH, and chronic renal failure, possibly influenced both severity and lethality in these patients. Likewise, this work evidenced a lethality of 50% in patients with fungal coinfections, similar to that reported by Sayedjavadi et al. (14), who conducted a systematic review study of cases or case series of COVID-19 patients with fungal coinfection reported during the period of January 1, 2020, to November 30, 2021, and determined a case fatality rate of 54.6%. In our study, the case fatality rate determined in COVID-19 patients with fungal superinfections was 22.2%. In this way, several authors have reported that both coinfection and fungal superinfection



negatively influence the progression and prognosis of the SARS-CoV-2 disease, particularly in critically ill patients (8,9,14).

It is crucial to mention that the interpretation of the COVID-19 impact on the development of fungal coinfections/superinfections must be cautious, as it involves different elements, such as the immune host defenses, the virulence of co-infecting pathogens, and risk factors (43). For example, in this study, *Candida* coinfections/superinfections (candidemia and candiduria) were associated with frequent predisposing factors, i.e., aspects that make any ICU patient vulnerable, such as the use of broad-spectrum antimicrobials, mechanical pulmonary ventilation, and prolonged hospital stay (44). One of the processes worth highlighting is the colonization of *Candida* spp. in various mucous membranes, which can lead to severe infection, especially candidemia. Therefore, COVID-19 does not appear to contribute to increased susceptibility to candidiasis (43).

Although during the pandemic, there was a 10-time increase in the incidence of candidiasis, particularly candidemias caused by *C. albicans*, the increase was observed both in COVID-19 patients and patients with other morbidities (45).

Likewise, the mortality rate showed no statistically significant difference between the populations of COVID-19 patients and subjects without coronavirus infection (46). Therefore, it is complex to determine whether SARS-CoV-2 infection actually leads to secondary *Candida* infection (47).

Nonetheless, there is evidence that severe viral infections, such as influenza A, can lead to concomitant *Aspergillus* spp. infections with a high mortality rate (48). A likely explanation is that phagolysosome maturation in

neutrophils and monocytes is altered after viral infection, limiting the ability of these cells to eliminate *Aspergillus* spp. (49), in such a way that the fungus can proliferate easily and cause infections, and they occurred in two forms: saprophytic pulmonary (aspergillomas) and invasive pulmonary. Some studies have shown that influenza can not only affect local phagocytosis of alveolar macrophages but can also limit the functionality of natural killer (NK) cells, cause cytokine imbalance, affect the Th1/Th2 response, and generate lymphopenia, leading to increased patient vulnerability to secondary infections (48,50,51). In addition to impaired local immunity, the influenza virus has been reported to alter the respiratory epithelium, cause loss of barrier function and decreased cilia movement, which may promote viral spread to the deeper lung parenchyma and create a favorable environment for the establishment of *Aspergillus* and other pathogens (43,48).

However, the mechanism of intrinsic immune dysregulation caused by the influenza virus and SARS-CoV-2 is unknown. Recently, some pathophysiology-related hypotheses have been laid out that may explain the development of COVID-19-associated aspergillosis. The first hypothesis is linked to the dysfunctional response of type I and III interferons (IFNs) in severe COVID-19 patients, which has a fundamental role against *Aspergillus* spp. Because it promotes the response of type 1 T helper cells against the fungus and drives the production of type III IFN, it causes neutrophils to act against *A. fumigatus*. The second hypothesis is related to IFN dysregulation, along with cell depletion of alveolar macrophages specifically, as they are the first cells to recognize inhaled conidia, thus being another possible cause of invasion by *Aspergillus* spp. (52-54).

It is possible that the different variants of the SARS-CoV-2 coronavirus influence to a greater or lesser extent, the incidence of secondary aspergillosis, similar to influenza A and B viruses (48). However, this is something that has yet to be studied.

It must be noted that this study has some limitations. At the time of hospital admission, patients were not screened for fungal pathogens, so possibly many coinfections were not detected, particularly in patients who died shortly after being admitted to the hospital. In addition, it is a retrospective study in which infections are reported based solely on mycological isolation documentation. The latter is disadvantageous as it is not always possible to isolate pathogens. Unfortunately, no molecular tests were performed to search and identify fungi in the study population, so fungal infections were likely underdiagnosed. However, our results support that patients with severe SARS-CoV-2 infection need to be routinely screened for both fungal and other microorganism infections in a timely manner (55,56). This measure will be helpful for decision-making during the therapeutic management of patients and for achieving a better prognosis. Likewise, the use of empirical antifungal therapy at the early stage of the SARS-CoV-2 infection may be a wise choice, as some of the secondary infections are not linked to the respiratory presentation but are urinary tract or bloodstream infections (2,18), as shown in our findings.

In conclusion, the rate of fungal coinfections/superinfections in COVID-19 patients was low, with adult males being the most affected population. Urinary tract and bloodstream infections were the primary clinical forms caused by *C. albicans*, *C.*

*tropicalis*, *C. glabrata*, *K. marxianus* (*C. kefyr*), and *C. lusitaniae*. Meanwhile, only one case of tracheobronchitis by *A. fumigatus* was found. Prolonged hospital stays, extended mechanical ventilation, corticosteroids, and broad-spectrum antibiotics, as well as diabetes mellitus, were the main risk factors for developing fungal infections; however, the interpretation of the COVID-19 impact on the development of fungal coinfections/superinfections must be cautious. Based on these findings, routine screening to identify fungi in patients with severe SARS-CoV-2 is recommended to timely detect fungal infections that may further compromise the patient's life.

### **Acknowledgments**

To Araceli Carmona Sánchez for her support in the search for clinical records. To Guadalupe Rosa Dueñas Donnadiou for her invaluable support.

### **Conflicts of interest**

The authors declare no conflict of interest.

### **Funding**

This research received no external funding.

### **References**

1. **Lansbury L, Lim B, Baskaran V, Lim WS.** Co-infections in people with COVID-19: a systematic review and meta-analysis. *J Infect.* 2020;81:26675. <https://doi.org/10.1016/j.jinf.2020.05.046>
2. **Peng J, Wang Q, Mei H, Zheng H, Liang G, She X, et al.** Fungal co-infection in COVID-19 patients: evidence from a systematic review and

meta-analysis. *Aging* (Albany, NY). 2021;13:7745-57.

<https://doi.org/10.18632/aging.202742>

3. **Hoeningl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al.**

COVID-19-associated fungal infections. *Nat Microbiol.* 2022;7:1127-40.

<https://doi.org/10.1038/s41564-022-01172-2>

4. **Soni S, Namdeo Pudake R, Jain U, Chauhan N.** A systematic review on

SARS-CoV-2-associated fungal coinfections. *J Med Virol.* 2022;94:99-109.

<https://doi.org/10.1002/jmv.27358>

5. **Pipitone G, Spicola D, Abbott M, Sanfilippo A, Onorato F, Di Lorenzo F,**

**et al.** Invasive cryptococcal disease in COVID-19: systematic review of the literature and analysis. *Infez Med.* 2023;31:6-12.

<https://doi.org/10.53854/liim-3101-2>

6. **Antinori S, Galimberti L, Milazzo L, Ridolfo AL.** Bacterial and fungal

infections among patients with SARS-CoV-2 pneumonia. *Infez Med.*

2020;28(suppl 1):29-36.

7. **Kuehn BM.** Pulmonary fungal infections affect patients with COVID-19.

*JAMA.* 2020;324:2248. <https://doi.org/10.1001/jama.2020.22914>

8. **Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen**

**L, Safdar N.** Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-

analysis. *PLoS One.* 2021;16:e0251170.

<https://doi.org/10.1371/journal.pone.0251170>

9. **Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al.** The microbial coinfection in COVID-19. *Appl Microbiol Biotechnol.* 2020;104:7777-85.  
<https://doi.org/10.1007/s00253-020-10814-6>
10. **Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, et al.** *Candida auris* outbreak in a COVID-19 specialty care unit - Florida, July-August 2020. *MMWR Morb Mortal Wkly Rep.* 2021;70:56-7.  
<https://doi.org/10.15585/mmwr.mm7002e3>
11. **Villanueva-Lozano H, Treviño-Rangel RJ, González GM, Ramírez-Elizondo MT, Lara-Medrano R, Aleman-Bocanegra MC, et al.** Outbreak of *Candida auris* infection in a COVID-19 hospital in Mexico. *Clin Microbiol Infect.* 2021;27:813-6. <https://doi.org/10.1016/j.cmi.2020.12.030>
12. **Frías-De-León MG, Pinto-Almazán R, Hernández-Castro R, García-Salazar E, Meza-Meneses P, Rodríguez-Cerdeira C, et al.** Epidemiology of systemic mycoses in the COVID-19 pandemic. *J Fungi (Basel).* 2021;7:556. <https://doi.org/10.3390/jof7070556>
13. **Sekaran A, Patil N, Sabhapandit S, Sistla SK, Reddy DN.** Rhino-orbito-cerebral mucormycosis: an epidemic in a pandemic. *IJID Reg.* 2022;2:99-106. <https://doi.org/10.1016/j.ijregi.2021.12.009>
14. **Seyedjavadi SS, Bagheri P, Nasiri MJ, Razzaghi-Abyaneh M, Goudarzi M.** Fungal infection in co-infected patients with COVID-19: An overview of case reports/case series and systematic review. *Front Microbiol.* 2022;13:888452. <https://doi.org/10.3389/fmicb.2022.888452>

15. **Cattaneo L, Buonomo AR, Iacovazzo C, Giaccone A, Scotto R, Viceconte G, et al.** Invasive fungal infections in hospitalized patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves. *J Fungi (Basel)*. 2023;9:86.  
<https://doi.org/10.3390/jof9010086>
16. **Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al.** Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. *J Clin Virol*. 2020;127:104364. <https://doi.org/10.1016/j.jcv.2020.104364>
17. **Kurra N, Woodard PI, Gandrakota N, Gandhi H, Polisetty SR, Ang SP, et al.** Opportunistic infections in COVID-19: A systematic review and meta-analysis. *Cureus*. 2022;14:e23687. <https://doi.org/10.7759/cureus.23687>
18. **Pakzad R, Malekifar P, Shateri Z, Zandi M, Akhavan Rezayat S, Soleymani M, et al.** Worldwide prevalence of microbial agents' coinfection among COVID-19 patients: A comprehensive updated systematic review and meta-analysis. *J Clin Lab Anal*. 2022;36:e24151.  
<https://doi.org/10.1002/jcla.24151>
19. **Soltani S, Zandi M, Faramarzi S, Shahbahrami R, Vali M, Rezayat SA, et al.** Worldwide prevalence of fungal coinfections among COVID-19 patients: a comprehensive systematic review and meta-analysis. *Osong Public Health Res Perspect*. 2022;13:15-23.  
<https://doi.org/10.24171/j.phrp.2021.0293>
20. **Azoulay E, Russell L, Van de Louw A, Metaxa V, Bauer P, Povoas P, et al.** Diagnosis of severe respiratory infections in immunocompromised

patients. Intensive Care Med. 2020;46:298-314.

<https://doi.org/10.1007/s00134-019-05906-5>

21. **Rawson TM, Wilson RC, Holmes A.** Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021;27:9-11.  
<https://doi.org/10.1016/j.cmi.2020.09.025>
22. **Melhem MS, Bertoletti A, Lucca HR, Silva RB, Meneghin FA, Szesz MW.** Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species. Braz J Microbiol. 2014;44:1257-1266. <https://doi.org/10.1590/S1517-83822014005000018>
23. **Piontelli LE.** Aportes morfotaxonómicos en el género *Aspergillus* Link: Claves para las especies ambientales y clínicas más comunes. Boletín Micológico. 2008;23:49-66.
24. **Saludness.** Hospital Regional de Alta Especialidad de Ixtapaluca. Consulted: March 20, 2023. Available in: <https://his.hraei.gob.mx/>
25. **World Health Organization.** WHO COVID-19 dashboard. Consulted: May 31, 2023. Available in: <https://data.who.int/dashboards/covid19/cases?n=c>
26. **Gu J, Korteweg C.** Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170:1136-47.  
<https://doi.org/10.2353/ajpath.2007.061088>
27. **Milne-Price S, Miazgowicz KL, Munster VJ.** The emergence of the Middle East respiratory syndrome coronavirus. Pathog Dis. 2014;71:121-36.  
<https://doi.org/10.1111/2049-632X.12166>



28. **MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al.** The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza A(H1N1)pdm09. *BMC Infect Dis.* 2018;18:637. <https://doi.org/10.1186/s12879-018-3548-0>
29. **Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, et al.** Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. *Intensive Care Med.* 2020;46:1524-35. <https://doi.org/10.1007/s00134-020-06091-6>
30. **Salazar F, Bignell E, Brown GD, Cook PC, Warris A.** Pathogenesis of respiratory viral and fungal coinfections. *Clin Microbiol Rev.* 2022;35:e0009421. <https://doi.org/10.1128/CMR.00094-21>
31. **Park SY, Lim C, Lee SO, Choi SH, Kim YS, Woo JH, et al.** Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value. *J Infect.* 2011;63:447-56. <https://doi.org/10.1016/j.jinf.2011.08.007>
32. **Roman-Montes CM, Bojorges-Aguilar S, Corral-Herrera EA, Rangel-Cordero A, Díaz-Lomelí P, Cervantes-Sanchez A, et al.** Fungal infections in the ICU during the COVID-19 pandemic in Mexico. *J Fungi (Basel).* 2023;9:583. <https://doi.org/10.3390/jof9050583>
33. **Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al.** Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective

cohort study. *Clin Microbiol Infect.* 2021;27:83-8.

<https://doi.org/10.1016/j.cmi.2020.07.041>

34. **Hope WW, Walsh TJ, Denning DW.** Laboratory diagnosis of invasive aspergillosis. *Lancet Infect Dis.* 2005;5:609-22.  
[https://doi.org/10.1016/S1473-3099\(05\)70238-3](https://doi.org/10.1016/S1473-3099(05)70238-3)
35. **Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al.** Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. *Clin Microbiol Infect.* 2021;27:451-7.  
<https://doi.org/10.1016/j.cmi.2020.10.021>
36. **Nebreda-Mayoral T, Miguel-Gómez MA, March-Rosselló GA, Puente-Fuertes L, Cantón-Benito E, Martínez-García AM, et al.** Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain. *Enferm Infecc Microbiol Clin.* 2022;40:158-65. <https://doi.org/10.1016/j.eimce.2022.02.002>
37. **Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.** Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395:1054-62.  
[https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
38. **Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, et al.** Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: A prospective study. *Clin Infect Dis.* 2021;73:e3606-e3614. <https://doi.org/10.1093/cid/ciaa1065>

39. **Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R, Mertes H, et al.** COVID-19-associated invasive pulmonary aspergillosis. *Ann Intensive Care*. 2020;10:71. <https://doi.org/10.1186/s13613-020-00686-4>
40. **van de Veerdonk FL, Brüggemann RJM, Vos S, De Hertogh G, Wauters J, Reijers MHE, et al.** COVID-19-associated *Aspergillus* tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. *Lancet Respir Med*. 2021;9:795-802. [https://doi.org/10.1016/S2213-2600\(21\)00138-7](https://doi.org/10.1016/S2213-2600(21)00138-7)
41. **Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al.** Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infect Dis*. 2021;21:e149-e62. [https://doi.org/10.1016/S1473-3099\(20\)30847-1](https://doi.org/10.1016/S1473-3099(20)30847-1)
42. **Li Z, Denning DW.** The impact of corticosteroids on the outcome of fungal disease: A systematic review and meta-analysis. *Curr Fungal Infect Rep*. 2023;17:54-70. <https://doi.org/10.1007/s12281-023-00456-2>
43. **Mina S, Yaakoub H, Annweiler C, Dubée V, Papon N.** COVID-19 and fungal infections: a double debacle. *Microbes Infect*. 2022;24:105039. <https://doi.org/10.1016/j.micinf.2022.105039>
44. **Yapar N.** Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag*. 2014;10:95-105. <https://doi.org/10.2147/TCRM.S40160>
45. **Arastehfar A, Carvalho A, Nguyen MH, Hedayati MT, Netea MG, Perlin DS, et al.** COVID-19-associated candidiasis (CAC): An underestimated

- complication in the absence of immunological predispositions? *J Fungi* (Basel). 2020;6:211. <https://doi.org/10.3390/jof6040211>
46. **Buil JB, Schouten JA, Wauters J, van de Hoeven H, Verweij PE; CAC-SDD study group.** Absence of candidemia in critically ill patients with COVID-19 receiving selective digestive decontamination. *Intensive Care Med.* 2022;48:611-2. <https://doi.org/10.1007/s00134-022-06651-y>
47. **Kundu R, Singla N.** COVID-19 and plethora of fungal infections. *Curr Fungal Infect Rep.* 2022;16:47-54. <https://doi.org/10.1007/s12281-022-00432-2>
48. **Crum-Cianflone NF.** Invasive aspergillosis associated with severe influenza infections. *Open Forum Infect Dis.* 2016;3:ofw171. <https://doi.org/10.1093/ofid/ofw171>
49. **Liu KW, Grau MS, Jones JT, Wang X, Vesely EM, James MR, et al.** Postinfluenza environment reduces *Aspergillus fumigatus* conidium clearance and facilitates invasive aspergillosis *in vivo*. *mBio.* 2022;13:e0285422. <https://doi.org/10.1128/mbio.02854-22>
50. **Lee N, Wong CK, Chan PK, Chan MC, Wong RY, Lun SW, et al.** Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. *PLoS One.* 2011;6:e26050. <https://doi.org/10.1371/journal.pone.0026050>
51. **Shi SJ, Li H, Liu M, Liu YM, Zhou F, Liu B, et al.** Mortality prediction to hospitalized patients with influenza pneumonia: PO<sub>2</sub> /FiO<sub>2</sub> combined

lymphocyte count is the answer. Clin Respir J. 2017;11:352-60.

<https://doi.org/10.1111/crj.12346>

52. **Feys S, Almyroudi MP, Braspenning R, Lagrou K, Spriet I, Dimopoulos**

**G, et al.** A Visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA). J Fungi (Basel). 2021;7:1067.

<https://doi.org/10.3390/jof7121067>

53. **Castro-Fuentes CA, Reyes-Montes MD, Frías-De-León MG, Valencia-**

**Ledezma OE, Acosta-Altamirano G, Duarte-Escalante E.** *Aspergillus*-SARS-CoV-2 Coinfection: What Is Known? Pathogens. 2022;11:1227.

<https://doi.org/10.3390/pathogens11111227>

54. **Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R,**

**et al.** Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 2012;38:1761-

8. <https://doi.org/10.1007/s00134-012-2673-2>

55. **Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al.** Co-infection with

respiratory pathogens among COVID-2019 cases. Virus Res.

2020;285:198005. <https://doi.org/10.1016/j.virusres.2020.198005>

56. **White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al.** A

national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. Clin Infect Dis. 2021;73:e1634-

e1644. <https://doi.org/10.1093/cid/ciaa1298>

**Table 1.** Characteristics of hospitalized COVID-19 patients who presented fungal coinfection/superinfection.

Patient No.	Sex	Age (years)	COVID-19 Treatment	Comorbidities	Hospital stay (days)	Predisposing factors	Ferritin (ng/mL)	Type of infection (superinfection /coinfection)	Type of mycosis (etiology)	Antifungal treatment	Outcome (deceased/cured)
1	Male	43	Azithromycin, Piperacillin/T azobactam, Linezolid, Paracetamol	Ischemic CVD, cerebral edema, chronic ischemic heart disease, acute coronary syndrome, metabolic syndrome, obstructive sleep apnea, non-purulent moderate soft tissue infection, peripheral arterial insufficiency, acute kidney injury, DM2, morbid obesity	11	ICU	996.9*	Coinfection	Candiduria ( <i>C. albicans</i> )	Did not receive	Deceased
2	Male	58	Methylprednisolone, Cefepime, paracetamol	Alcoholism	56	ICU, mechanical ventilation, use of broad-spectrum antibiotics	936.4*	Coinfection	Candiduria ( <i>C. albicans</i> )	Voriconazole	Cured
3	Male	51	Methylprednisolone, hydroxychloroquine sulfate,	No comorbidities	23	Prolonged ICU, mechanical ventilation	673.9*	Superinfection	Candiduria ( <i>C. albicans</i> )	Fluconazole	Deceased

			azithromycin, ceftriaxone								
4	Female	26	Dexamethasone Azithromycin, vancomycin	Myeloid leukemia	16	ICU	745.4*	Superinfection	Candiduria ( <i>C. tropicalis</i> and <i>C. kefyr</i> )	Fluconazole	Cured
5	Male	44	Tocilizumab, nitric oxide, azithromycin, ceftriaxone	No comorbidities	15	ICU, mechanical ventilation	523.1*	Superinfection	Candiduria ( <i>C. albicans</i> )	Fluconazole	Cured (the patient requested discharge while in serious condition)
6	Female	22	Dexamethasone, chloropyramine, paracetamol	Gestational type 2 diabetes mellitus, acute lymphoblastic leukemia, obesity, post-hysterectomy pathological puerperium, obstetric hemorrhage, ischemic CVD, DM2, axillary DVT, moderate depression	21	ICU	900.9*	Superinfection	Candidemia ( <i>C. tropicalis</i> )	Did not receive	Cured
7	Male	61	Paracetamol	DM2, SAH, Stage 1 chronic kidney disease	24	ICU, mechanical ventilation	1622*	Superinfection	Candiduria ( <i>C. albicans</i> )	Fluconazole	Deceased
8	Male	72	Levofloxacin, azithromycin	Mixed dyslipidemia, Acute Kidney Injury KDIGO I	40	ICU, mechanical ventilation	456.4*	Superinfection	Candidemia ( <i>C. lusitanae</i> )	Caspofungin	Cured

<b>9</b>	Female	58	Dexamethasone, paracetamol, meropenem	DM2, SAH, Broad-spectrum antibiotics (vancomycin, amikacin, meropenem)	19	ICU, mechanical ventilation	528.3*	Superinfection	Candiduria ( <i>C. glabrata</i> )	Caspofungin	Cured
<b>10</b>	Male	61	Dexamethasone, Amikacin, Vancomycin	DM2, vitamin D deficiency.	33	Prolonged ICU, required mechanical ventilation twice	696.4*	Superinfection	Candiduria ( <i>C. tropicalis</i> )	Caspofungin	Cured
<b>11</b>	Male	59	Vancomycin, gentamicin	Tracheostomy, DM2, acute kidney disease, acute bile reflux gastropathy, SAH	65	ICU, mechanical ventilation	1159.3*	Superinfection	Tracheobronchitis ( <i>Aspergillus fumigatus</i> )	Caspofungin	Cured (without sequelae)

ICU: Intensive Care Unit; CVD: Cardiovascular Disease; DM2: Diabetes Mellitus, type 2; DVT: Deep Vein Thrombosis; SAH: Systemic Arterial Hypertension; KDIGO: Kidney Disease Improving Global Outcomes. \*Values outside the normal range.